Low-Dose Atropine Not FDA Approved: What the STAR Study Means for Today’s Myopia Control Practices

episode

Defocus Media Eyecare and Optometry Podcast Network not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

A.I. Safety Goes Mainstream + a ‘Hard Fork’ Exit AMA 1h 25m · 18 Sep 2026 · Hard Fork

Layoffs at the Kansas City Star will hurt local communities 15 min · 18 Sep 2026 · Kansas City Today

NPR News: 09-17-2026 8PM EDT 4 min · 18 Sep 2026 · NPR News Now

8PM ET 09/17/2026 Newscast 3 min · 18 Sep 2026 · Fox News Hourly Update

2948: The Type of Exercise That Will Get You Past Sticking Points & Why This Beats Every Other Form of Exercise 1h 13m · 18 Sep 2026 · Mind Pump: Raw Fitness Truth

What's Wright - Lions-Bills Predictions, is Patrick Mahomes BACK? Jaguars Super Bowl CONTENDERS? 1h 5m · 18 Sep 2026 · The Herd with Colin Cowherd

Report any issue

Source

Recorded08 Dec 2025

Publisherdefocusmediagroup.com ↗

Handlerec:14363553

Show notes

The topic of low-dose atropine, not FDA-approved, has become one of the most important conversations in pediatric eye care this year, especially as clinicians turn to the STAR Study for clarity on atropine’s role in modern myopia control. The STAR Study is the largest and most ethnically diverse atropine study to date, evaluating 0.01% and 0.03% atropine versus placebo in more than 800 children across three countries.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in